A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors
- PMID: 28429247
- PMCID: PMC5427147
- DOI: 10.1007/s12325-017-0532-9
A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors
Abstract
Proton pump inhibitors (PPIs) are known as a class of pharmaceutical agents that target H+/K+-ATPase, which is located in gastric parietal cells. PPIs are widely used in the treatment of gastric acid-related diseases including peptic ulcer disease, erosive esophagitis and gastroesophageal reflux disease, and so on. These drugs present an excellent safety profile and have become one of the most commonly prescribed drugs in primary and specialty care. Except for gastric acid-related diseases, PPIs can also be used in the treatment of Helicobacter pylori infection, viral infections, respiratory system diseases, cancer and so on. Although PPIs are mainly used short term in patients with peptic ulcer disease, nowadays these drugs are increasingly used long term, and frequently for a lifetime, for instance in patients with typical or atypical symptoms of gastroesophageal reflux disease and in NSAID or aspirin users at risk of gastrotoxicity and related complications including hemorrhage, perforation and gastric outlet obstruction. Long-term use of PPIs may lead to potential adverse effects, such as osteoporotic fracture, renal damage, infection (pneumonia and clostridium difficile infection), rhabdomyolysis, nutritional deficiencies (vitamin B12, magnesium and iron), anemia and thrombocytopenia. In this article, we will review some novel uses of PPIs in other fields and summarize the underlying adverse reactions.
Keywords: Adverse effects; Erosive esophagitis; Gastric acid-related diseases; Gastroenterology; Gastroesophageal reflux disease; Helicobacter pylori infection; Peptic ulcer disease; Proton pump inhibitors.
Similar articles
-
AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review.Gastroenterology. 2024 Nov;167(6):1228-1238. doi: 10.1053/j.gastro.2024.06.038. Epub 2024 Sep 11. Gastroenterology. 2024. PMID: 39269391 Review.
-
Guide to the use of proton pump inhibitors in adult patients.Drugs. 2008;68(7):925-47. doi: 10.2165/00003495-200868070-00004. Drugs. 2008. PMID: 18457460 Review.
-
Proton pump inhibitors: the good, the bad, and the unwanted.South Med J. 2012 Nov;105(11):613-8. doi: 10.1097/SMJ.0b013e31826efbea. South Med J. 2012. PMID: 23128806 Review.
-
Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics.Paediatr Drugs. 2013 Apr;15(2):119-31. doi: 10.1007/s40272-013-0012-x. Paediatr Drugs. 2013. PMID: 23512128 Free PMC article. Review.
-
The use of proton pump inhibitors in children: a comprehensive review.Paediatr Drugs. 2003;5(1):25-40. doi: 10.2165/00128072-200305010-00003. Paediatr Drugs. 2003. PMID: 12513104 Review.
Cited by
-
An Unusual Presentation of Iron-Deficiency Anemia: An Autobiographical Case Report.Cureus. 2021 Dec 15;13(12):e20442. doi: 10.7759/cureus.20442. eCollection 2021 Dec. Cureus. 2021. PMID: 35047279 Free PMC article.
-
Are Proton Pump Inhibitors Contributing in Emerging New Hypertensive Population?Pharmaceuticals (Basel). 2023 Sep 30;16(10):1387. doi: 10.3390/ph16101387. Pharmaceuticals (Basel). 2023. PMID: 37895858 Free PMC article. Review.
-
Associations Between Asthma Diagnosis/Asthma Exacerbation and Previous Proton-Pump Inhibitor use: A Nested Case-Control Study Using a National Health Screening Cohort.Front Pharmacol. 2022 Jun 30;13:888610. doi: 10.3389/fphar.2022.888610. eCollection 2022. Front Pharmacol. 2022. PMID: 35847037 Free PMC article.
-
Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences.Neural Plast. 2018 Mar 21;2018:5257285. doi: 10.1155/2018/5257285. eCollection 2018. Neural Plast. 2018. PMID: 29755512 Free PMC article. Review.
-
Rebamipide Prevents the Hemoglobin Drop Related to Mucosal-Damaging Agents at a Level Comparable to Proton Pump Inhibitors.Gut Liver. 2024 Nov 15;18(6):1026-1036. doi: 10.5009/gnl230372. Epub 2024 Mar 12. Gut Liver. 2024. PMID: 38468192 Free PMC article.
References
-
- Feng S, Cleary Y, Parrott N, Hu P, Weber C, Wang Y, et al. Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway. Eur J Clin Pharmacol. 2015;71(5):617–624. doi: 10.1007/s00228-015-1834-y. - DOI - PubMed
-
- Wang Y, Zhang H, Meng L, Wang M, Yuan H, Ou N, et al. Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers. Eur J Clin Pharmacol. 2010;66(6):563–569. doi: 10.1007/s00228-010-0821-6. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical